Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) EBT Margin (2016 - 2025)

CytomX Therapeutics' EBT Margin history spans 12 years, with the latest figure at 3990.35% for Q4 2025.

  • For Q4 2025, EBT Margin fell 404006.0% year-over-year to 3990.35%; the TTM value through Dec 2025 reached 22.48%, down 4572.0%, while the annual FY2025 figure was 22.48%, 4572.0% down from the prior year.
  • EBT Margin reached 3990.35% in Q4 2025 per CTMX's latest filing, down from 237.65% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 49.72% in Q4 2024 to a low of 3990.35% in Q4 2025.
  • Average EBT Margin over 5 years is 311.15%, with a median of 34.71% recorded in 2022.
  • Peak YoY movement for EBT Margin: surged 33968bps in 2023, then tumbled -404006bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 312.82% in 2021, then surged by 86bps to 43.61% in 2022, then surged by 116bps to 7.16% in 2023, then surged by 594bps to 49.72% in 2024, then crashed by -8126bps to 3990.35% in 2025.
  • Per Business Quant, the three most recent readings for CTMX's EBT Margin are 3990.35% (Q4 2025), 237.65% (Q3 2025), and 0.49% (Q2 2025).